FOLH1 and neoplasm: Responders according to PSMA-TV evaluation (7/21 patients 33%) had a mean averaged tumor dose of 10.7 ± 14.5 Gy/GBq compared to non-responders (14/21 patients 67%) with a mean tumor dose of 4.5 ± 3.6 Gy/GBq (p = 0.32) (Figure 5c).